|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61K 31/00 | (2006.01) |
| (11) | Number of the document | 2218461 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10162787.5 |
| Date of filing the European patent application | 2004-12-09 | |
| (97) | Date of publication of the European application | 2010-08-18 |
| (45) | Date of publication and mention of the grant of the patent | 2016-04-20 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 531639 P | 2003-12-22 | US |
| (72) |
Bedian, Vahe, US
Cusmano, John, Daniel, US
Gladue, Ronald, Paul, US
|
| (73) |
Pfizer Products Inc.,
Eastern Point Road, Groton, CT 06340,
US
|
| (54) | CD40 antibody formulation and methods |
| CD40 antibody formulation and methods |